Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2012, Pages 19-26

  Verhamme, K M C ^a   Afonso, A S M ^a   van Noord, C ^a   Haag, M D ^a   Koudstaal, P J ^a   Brusselle, G G O ^b   Sturkenboom, M C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardiovascular; Case control; Cerebrovascular; Cohort; COPD; Death; LABA; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; TIOTROPIUM BROMIDE; XANTHINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DATA BASE; DRUG SAFETY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADRENERGIC BETA-AGONISTS; ADULT; AGE FACTORS; AGED; ARRHYTHMIAS, CARDIAC; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEBULIZERS AND VAPORIZERS; ODDS RATIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SEX FACTORS; STROKE;

EID: 84856791095     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.10.004     Document Type: Article

References (26)

1. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine 2001 Apr, 163(5):1256-1276.
2. Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006 Oct, 61(10):854-862.
3. Lee T.A., Pickard A.S., Au D.H., Bartle B., Weiss K.B. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Annals of Internal Medicine 2008 Sep 16, 149(6):380-390.
4. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 Sep 24, 300(12):1439-1450.
5. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A4-year trial of tiotropium in chronic obstructive pulmonary disease. The New England Journal of Medicine 2008 Oct 9, 359(15):1543-1554.
6. Celli B., Decramer M., Kesten S., Liu D., Mehra S., Tashkin D.P. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2009 Nov 15, 180(10):948-955.
7. Michele T.M., Pinheiro S., Iyasu S. The safety of tiotropium - the FDA's conclusions. The New England Journal of Medicine 2010 Sep 16, 363(12):1097-1099.
8. van der Lei J., Duisterhout J.S., Westerhof H.P., van der Does E., Cromme P.V., Boon W.M., et al. The introduction of computer-based patient records in The Netherlands. Annals of Internal Medicine 1993 Nov 15, 119(10):1036-1041.
9. Lamberts H.W.M. International classification of primary care 1987.
10. DeSmet P. The Dutch approach to computerized drug information: conceptual basis and realization. Journal of Social and Administrative Pharmacy 1988, 5:49-58.
11. Vlug A.E., van der Lei J., Mosseveld B.M., van Wijk M.A., van der Linden P.D., Sturkenboom M.C., et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods of Information in Medicine 1999 Dec, 38(4-5):339-344.
12. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiology and Drug Safety 2005 Aug, 14(8):589-595.
13. Curkendall S.M., Lanes S., de Luise C., Stang M.R., Jones J.K., She D., et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. European Journal of Epidemiology 2006, 21(11):803-813.
14. Eisner M.D., Trupin L., Katz P.P., Yelin E.H., Earnest G., Balmes J., et al. Development and validation of a survey-based COPD severity score. Chest 2005 Jun, 127(6):1890-1897.
15. Soriano J.B., Maier W.C., Visick G., Pride N.B. Validation of general practitioner-diagnosed COPD in the UK general practice research database. European Journal of Epidemiology 2001, 17(12):1075-1080.
16. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. American Journal of Respiratory and Critical Care Medicine 2002 Aug 1, 166(3):333-339.
17. Lanes S., Golisch W., Mikl J. Ipratropium and lung health study. American Journal of Respiratory and Critical Care Medicine 2003 Mar 1, 167(5):801. author reply - 2.
18. FDA hwfgddpduh cited; Available from:. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforhealthcareprofessionals/ucm070651.htm.
19. Celli B., Decramer M., Leimer I., Vogel U., Kesten S., Tashkin D.P. Cardiovascular safety of tiotropium in patients with COPD. Chest 2009 Jul 10.
20. Oba Y., Zaza T., Thameem D.M. Safety, tolerability and risk benefit analysis of tiotropium in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2008, 3(4):575-584.
21. Rodrigo G.J., Castro-Rodriguez J.A., Nannini L.J., Plaza Moral V., Schiavi E.A. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respiratory Medicine 2009 Oct, 103(10):1421-1429.
22. de Luise C., Lanes S.F., Jacobsen J., Pedersen L., Sorensen H.T. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. European Journal of Epidemiology 2007, 22(4):267-272.
23. Jara M., Lanes S.F., Wentworth C., May C., Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Safety 2007, 30(12):1151-1160.
24. Gershon A., Croxford R., To T., Stanbrook M.B., Upshur R., Sanchez-Romeu P., et al. Comparison of inhaled long-acting {beta}-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Annals of Internal Medicine 2011 May 3, 154(9):583-592.
25. Vogelmeier C., Hederer B., Glaab T., Schmidt H., Rutten-van Molken M.P., Beeh K.M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. The New England Journal of Medicine 2011 Mar 24, 364(12):1093-1103.
26. Singh S., Loke Y.K., Enright P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. British Medical Journal 2011, 342:d3215.